GlassScriptPhysician profile
Girish Mohan
NPI 1093193161
$2,981.07
in general payments reported to CMS, 2019-2025
24 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.52 · 2020: $318 · 2021: $358 · 2022: $65.95 · 2023: $324 · 2024: $257 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.16 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $373.85 | 2023-2025 | Dupixent |
| Genzyme Corporation | $330.83 | 2020-2024 | |
| Lilly USA, LLC | $254.53 | 2019-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $251.63 | 2024-2025 | Tremfya |
| Ucb, INC. | $237.59 | 2019-2025 | Bimzelx |
| Amgen INC. | $229.25 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $203.16 | 2021-2025 | |
| Abbvie INC. | $185.87 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $147.05 | 2025 | Zoryve |
| Pfizer INC. | $130.59 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $105.43 | 2021-2025 | Blu-U, Odomzo |
| Biocon Biologics INC | $73.72 | 2025 | Yesintek |
| Leo Pharma INC. | $66.44 | 2025 | Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $63.51 | 2025 | Sotyktu |
| Mimedx Group, INC. | $60.40 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.48 | 2025 | |
| Dermira, INC. | $40.48 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $35.22 | 2023 | Nuzyra |
| Almirall LLC | $31.58 | 2021-2024 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.96 | 2020-2025 | Siliq, Jublia, Cabtreo |
| Incyte Corporation | $27.37 | 2022 | |
| Dermavant Sciences, INC. | $18.53 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $16.87 | 2021 | |
| Sebela Pharmaceuticals INC. | $13.73 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Girish Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.